254 related articles for article (PubMed ID: 32019910)
21. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of BRG1 silencing in primary cancers.
Marquez-Vilendrer SB; Thompson K; Lu L; Reisman D
Oncotarget; 2016 Aug; 7(35):56153-56169. PubMed ID: 27486753
[TBL] [Abstract][Full Text] [Related]
23. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
[TBL] [Abstract][Full Text] [Related]
24. A positive feedback loop involving the LINC00346/β-catenin/MYC axis promotes hepatocellular carcinoma development.
Zhang N; Chen X
Cell Oncol (Dordr); 2020 Feb; 43(1):137-153. PubMed ID: 31691159
[TBL] [Abstract][Full Text] [Related]
25. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
26. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
[TBL] [Abstract][Full Text] [Related]
27. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
28. Casein kinase 2-mediated phosphorylation of Brahma-related gene 1 controls myoblast proliferation and contributes to SWI/SNF complex composition.
Padilla-Benavides T; Nasipak BT; Paskavitz AL; Haokip DT; Schnabl JM; Nickerson JA; Imbalzano AN
J Biol Chem; 2017 Nov; 292(45):18592-18607. PubMed ID: 28939766
[TBL] [Abstract][Full Text] [Related]
29. PRAS40 hyperexpression promotes hepatocarcinogenesis.
Qi Z; Zhang T; Song L; Fu H; Luo H; Wu J; Zhao S; Zhang T; Guo L; Jin L; Zhang H; Huang G; Ma T; Wu Y; Huang L
EBioMedicine; 2020 Jan; 51():102604. PubMed ID: 31901857
[TBL] [Abstract][Full Text] [Related]
30. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated Nrf2/HO-1 transcriptional activation in human and mice.
Ge M; Chen H; Zhu Q; Cai J; Chen C; Yuan D; Jin Y; Yao W; Hei Z
J Cell Mol Med; 2017 Dec; 21(12):3693-3704. PubMed ID: 28749008
[TBL] [Abstract][Full Text] [Related]
31. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
32. The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Apr; 53(4):e12791. PubMed ID: 32162380
[TBL] [Abstract][Full Text] [Related]
33. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.
Lu M; Hartmann D; Braren R; Gupta A; Wang B; Wang Y; Mogler C; Cheng Z; Wirth T; Friess H; Kleeff J; Hüser N; Sunami Y
BMC Cancer; 2019 Sep; 19(1):887. PubMed ID: 31488102
[TBL] [Abstract][Full Text] [Related]
35. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X
Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642
[TBL] [Abstract][Full Text] [Related]
36. C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li SG; Shi QW; Yuan LY; Qin LP; Wang Y; Miao YQ; Chen Z; Ling CQ; Qin WX
J Exp Clin Cancer Res; 2018 Mar; 37(1):51. PubMed ID: 29523159
[TBL] [Abstract][Full Text] [Related]
37. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
[TBL] [Abstract][Full Text] [Related]
38. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.
Tey SK; Tse EYT; Mao X; Ko FCF; Wong AST; Lo RC; Ng IO; Yam JWP
Cancer Lett; 2017 Dec; 411():150-161. PubMed ID: 28989054
[TBL] [Abstract][Full Text] [Related]
39. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
40. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
